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Abstract
Introduction: Latinos living with HIV in the Americas share a common ethnic and cultural heritage. In North America, Latinos
have a relatively high rate of new HIV infections but lower rates of engagement at all stages of the care continuum, whereas in
Latin America antiretroviral therapy (ART) services continue to expand to meet treatment needs. In this analysis, we compare
HIV treatment outcomes between Latinos receiving ART in North America versus Latin America.
Methods: HIV-positive adults initiating ART at Caribbean, Central and South America Network for HIV (CCASAnet) sites were
compared to Latino patients (based on country of origin or ethnic identity) starting treatment at North American AIDS Cohort
Collaboration on Research and Design (NA-ACCORD) sites in the United States and Canada between 2000 and 2011. Cox
proportional hazards models compared mortality, treatment interruption, antiretroviral regimen change, virologic failure and
loss to follow-up between cohorts.
Results: The study included 8400 CCASAnet and 2786 NA-ACCORD patients initiating ART. CCASAnet patients were younger
(median 35 vs. 37 years), more likely to be female (27% vs. 20%) and had lower nadir CD4 count (median 148 vs. 195 cells/mL,
pB0.001 for all). In multivariable analyses, CCASAnet patients had a higher risk of mortality after ART initiation (adjusted hazard
ratio (AHR) 1.61; 95% confidence interval (CI): 1.32 to 1.96), particularly during the first year, but a lower hazard of treatment
interruption (AHR: 0.46; 95% CI: 0.42 to 0.50), change to second-line ART (AHR: 0.56; 95% CI: 0.51 to 0.62) and virologic failure
(AHR: 0.52; 95% CI: 0.48 to 0.57).
Conclusions: HIV-positive Latinos initiating ART in Latin America have greater continuity of treatment but are at higher risk of
death than Latinos in North America. Factors underlying these differences, such as HIV testing, linkage and access to care,
warrant further investigation.
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Introduction
In 2012, the World Health Organization (WHO) estimated
there were 1.3 million HIV-positive individuals in the United
States and Canada and 1.5 million in the countries of Latin
America (including Mexico) [1]. In the United States, over
16% of individuals self-identified as Hispanic or Latino in the
2010 US census (defined as persons of Cuban, Mexican,
Puerto Rican, South or Central American or other Spanish
culture or origin regardless of race). Latinos in the United
States have a rate of new HIV infections approximately three
times greater than among non-Hispanic whites, but lower
rates of engagement at all stages of the care continuum [24].
US Latinos are also more likely to be diagnosed with HIV at
later disease stages, and disparities in obtaining medical care
can be exacerbated by a lack of insurance, linguistic barriers,
stigma and differences in patient-provider communication
[58].
For HIV-positive Latinos in Mexico, Central America and
South America, the availability of HIV care and antiretroviral
therapy (ART) has expanded rapidly over the past decade,
with approximately 75% of the estimated 790,000 persons in
need of ART able to access treatment [1]. Latin America has
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diverse economic and social contexts, and prior studies have
found that mortality and programme retention vary con-
siderably between countries [912]. A recent analysis of six
Latin American countries and one Caribbean country found
that the overall mortality rate after five years of ART,
estimated to be 10%, was generally lower than that observed
in sub-Saharan Africa, but higher than that in Europe and
North America [1216], although rates were heterogeneous
between countries.
The goal of this study was to estimate regional differences
in clinical characteristics at ART initiation, mortality, ART
discontinuation or changes and virologic failure among HIV-
positive Latinos in the Americas. We compared outcomes of
HIV-positive Latino patients initiating ART in Canada and the
United States (hereafter referred to as North America) to
those in patients in six Latin American countries (Argentina,
Brazil, Chile, Honduras, Mexico and Peru) using the regional
databases of the International Epidemiologic Databases to
Evaluate AIDS (IeDEA) network.
Methods
Participants and settings
Patient-level HIV treatment and care data were aggregated
from two multinational regional consortia of IeDEA: the
Caribbean, Central and South America Network for HIV
research (CCASAnet) and the North American AIDS Cohort
Collaboration on Research and Design (NA-ACCORD). These
consortia have been profiled elsewhere [17,18].
Briefly, CCASAnet is a network of clinical sites in seven
diverse Caribbean, Central and South American countries
that pools data collected as part of HIV treatment and care
programmes. In this study, we included data from eight
CCASAnet sites in six countries: Hospital Ferna´ndez and
Centro Me´dico Hue´sped in Buenos Aires, Argentina (HF/
CMH-Argentina); Instituto Nacional de Infectologia Evandro
Chagas in Rio de Janeiro, Brazil (INI-Brazil); Fundacio´n Arriara´n
in Santiago, Chile (FA-Chile); Instituto Honduren˜o de Seguri-
dad Social and Hospital de Especialidades in Tegucigalpa,
Honduras (IHSS/HE-Honduras); Instituto Nacional de Ciencias
Me´dicas y Nutricio´n Salvador Zubira´n in Mexico City, Mexico
(INNSZ-Mexico); and Instituto de Medicina Tropical Alexander
von Humboldt in Lima, Peru (IMTAvH-Peru). The CCASAnet
site in Haiti was not included, given Haiti’s African ethnic
ancestry and non-Hispanic cultural heritage.
NA-ACCORD includes ]200 sites in 25 single and multisite
cohorts throughout the United States and Canada. In this
study, data from 11 NA-ACCORD clinical cohorts were
included: Fenway Community Health Center (Boston, MA),
HIV Research Network, Johns Hopkins HIV Clinical Cohort
(Baltimore, MD), Montreal Chest Institute Immunodeficiency
Service Cohort, Ontario HIV Treatment Network Cohort
Study, Retrovirus Research Center, Southern Alberta Clinic
Cohort, Study of the Consequences of the Protease Inhibitor
Era, University of Alabama at Birmingham 1917 Clinic Cohort,
University of Washington HIV Cohort and Vanderbilt-Meharry
Centers for AIDS Research (CFAR) Cohort. These sites
included patients from 17 US states, Puerto Rico, and 4
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Figure 1. Geographic distribution of NA-ACCORD and CCASAnet patients included in the analysis cohort.
Cesar C et al. Journal of the International AIDS Society 2016, 19:20684
http://www.jiasociety.org/index.php/jias/article/view/20684 | http://dx.doi.org/10.7448/IAS.19.1.20684
2
Canadian provinces (Figure 1). Latinos in NA-ACCORD were
identified based on either self-reported Hispanic ethnicity or
self-reported country of birth in South America, Central
America, Spanish-speaking countries in the Caribbean or
Mexico. The NA-ACCORD cohorts not included in the analysis
either did not have patients with Hispanic ethnicity or
declined to provide data.
Our analysis cohort was restricted to ART-naive adult HIV-
positive patients initiating ART between 2000 and 2011.
Patients with an undetectable HIV-1 RNA viral load (VL) prior
to reported date of ART initiation were excluded. Outcomes
wereassessedusingdata collected through31December 2011.
Clinical and epidemiological data were collected at each
centre, de-identified and sent to the Data Coordinating Center
at Vanderbilt University, USA. Institutional ethics review
boards from all sites and Vanderbilt approved the project,
waiving the requirement for individual patient informed
consent.
Outcomes
The time from ART initiation to each of five long-term
outcomes was assessed: all-cause mortality, treatment inter-
ruption, major treatment change, virologic failure and loss
to follow-up. ART was defined as a combination of three
antiretroviral agents from at least two classes, or a triple
nucleoside/nucleotide reverse transcriptase inhibitor regimen
containing abacavir or tenofovir. Patients without an event
were censored at 31 December 2011 or the date of their last
clinical, pharmacy or laboratory visit, whichever occurred first.
Participant deaths in NA-ACCORD are recorded by the
individual cohorts when the death can be confirmed, and
deaths among patients lost to care are ascertained using
routine surveillance andmatching of US national and Canadian
provincial death indexes. In CCASAnet, methods to ascertain
death differ across sites. At IHSS/HE-Honduras, deaths are
recorded after field workers contact patient family members
following a missed visit. At all other sites, deaths occurring at
affiliated hospitals or other clinical sites are recorded, as are
notifications of deaths by relatives of patients. Additionally,
study staff at INI-Brazil, FA-Chile, INNSZ-Mexico and IMTAvH-
Peru sites query government death registry databases for
patients lost to care at least annually.
Treatment interruption was defined as an interruption
of the initial ART regimen for 14 days. Major treatment
change included switching to a ‘‘second-line’’ regimen, defi-
ned as (1) a change to a boosted protease inhibitor (PI)-based
regimen; (2) switching to a different PI if a patient’s first
regimen included a boosted PI; (3) switching to a ‘‘third-line’’
drug (darunavir, tipranavir, etravirine, enfuvirtide, maraviroc or
raltegravir); or (4) changing to non-nucleoside reverse tran-
scriptase inhibitor (NNRTI), boosted PI or switching, deleting or
adding a third-line drug for those patients who had started
treatment on a third-line drug. Virologic failure was defined as
at least one of the following: (1) VL 400 copies/mL after six
months of therapy, (2) VL B400 copies/mL followed by a
single value 1000 copies/mL or (3) VL B400 copies/mL
followed by two consecutive VL 400 copies/mL. The
threshold of 400 copies/mLwas chosen based on the detection
limit for assays used at many of the sites during the study
period. Patients who did not have a VLmeasurement after ART
initiation were excluded from the virologic failure analyses.
Patients who had a gap between VL measurements of greater
than one year were censored at the last measurement prior to
the gap. Loss to follow-up (LFU) was defined as lack of
information about the patient within 180 days prior to the
database closing date; for patients lost to follow-up, the date of
LFU was defined as date of their last visit.
Statistical analysis
Univariate comparisons were performed using Wilcoxon
rank sum and chi-square tests. Kaplan-Meier estimates and
corresponding confidence intervals (CIs) of the probability of
mortality were calculated for each consortium.The cumulative
incidence and corresponding 95% CI of treatment interrup-
tion, ART regimen change and virologic failure were also
estimated and these models accounted for mortality as a
competing risk. Separate multivariable Cox proportional
hazards models were fit to compare the hazard of death,
major treatment modification and treatment failure between
patients in CCASAnet and NA-ACCORD. All multivariable
models were adjusted for age, sex, reported mode of
transmission, nadir CD4 T-cell count (CD4 count) and clinical
AIDS prior to treatment initiation, initial ART regimen and
year of ART initiation. Restricted cubic splines were used for
continuous variables to account for non-linear trends [19].
Multiple imputation was implemented to impute missing
covariate values [20].
Different frequencies of VL measurement between cohorts
may have biased the results since patients with more VL
measurements had more opportunities to be classified as a
treatment failure. We thus compared the incidence of a
detectable VL greater than six months after ART initiation
while accounting for the number of VL measurements using
a multivariable negative binomial regression model. We
report the adjusted relative proportions of detectable VL
per measurement and corresponding 95% CI.
Brazilian HIV treatment sites contributing data to CCASA-
net were included in the primary analysis, as were Brazilian
patients living in the United States or Canada and enrolled in
NA-ACCORD (the US census definition of Latino includes
Brazilians). However, the ethnic heritage of Brazil includes a
large component of African migration, and we performed
subregion analyses which excluded patients initiating ART
in Brazil and patients born in Brazil initiating ART in North
America. We also performed a subregion analysis comparing
NA-ACCORD patients reporting Mexico as their country of
origin with CCASAnet patients from Mexico.
All analyses were performed using R version 3.1.2;
analysis code is available at www.biostat.mc.vanderbilt.edu/
ArchivedAnalyses.
Results
From 2000 to 2011, a total of 11,186 ART-naive Latino
patients initiated ART at one of 19 sites; 8400 (75%) at one of
8 CCASAnet sites in Latin America and 2786 (25%) in one of
11 NA-ACCORD cohorts with clinical sites in 17 US states and
4 Canadian provinces (Figure 1). CCASAnet patients included
2041 initiating ART in Argentina, 1792 in Brazil, 1347 in Chile,
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882 in Honduras, 804 in Mexico and 1534 in Peru. Latinos
initiating ART in North America included 294 with a known
country of birth (156 from Mexico, 40 from other Central
American countries, 69 from South American countries and
29 from the United States); the remaining 2492 patients self-
reported as Latino.
Table 1. Description of cohort participants at antiretroviral therapy initiation
CCASAnet
(n8400)
NA-ACCORD
(n2786) p
Age, years 35 (29 to 43) 37 (30 to 44) B0.001
Sex B0.001
Female 2268 (27.0%) 550 (19.7%)
Male 6132 (73.0%) 2236 (80.3%)
Route of infection B0.001
Heterosexual 3841 (45.7%) 1040 (37.3%)
MSM 3248 (38.7%) 1313 (47.1%)
IDU 179 (2.1%) 336 (12.0%)
Other 63 (0.8%) 74 (2.7%)
Unknown 1069 (12.7%) 23 (0.9%)
Clinical stage B0.001
AIDS 2443 (29.1%) 605 (21.7%)
Not AIDS 4561 (54.3%) 1735 (62.3%)
Missing 1396 (16.6%) 446 (16.0%)
Nadir CD4 count, cells/mL 148 (54 to 246) 195 (68 to 298) B0.001
Missing 980 (11.7%) 170 (6.1%)
Baseline CD4 count, cells/mL 150 (55 to 253) 212 (79 to 323) B0.001
Missing 1422 (16.9%) 248 (9%)
Baseline viral load (log10) 5.0 (4.5 to 5.4) 4.8 (4.2 to 5.3) B0.001
Missing 2708 (32.2%) 345 (12.4%)
Initial regimen B0.001
NNRTI 6699 (79.8%) 1240 (44.5%)
Boosted PI 1183 (14.1%) 974 (35.0%)
Other 518 (6.2%) 572 (20.5%)
Nucleoside backbone B0.001
ZDV3TC 5604 (66.7%) 597 (21.4%)
TDFFTC 640 (7.6%) 1564 (56.1%)
TDF3TC 562 (6.7%) 127 (4.6%)
D4T3TC 873 (10.4%) 123 (4.4%)
ABC3TC 331 (3.9%) 183 (6.6%)
Other 390 (4.6%) 192 (6.9%)
Regimen anchor B0.001
EFV 5470 (65.1%) 1145 (41.1%)
NVP 1211 (14.4%) 83 (3.0%)
NFV 78 (0.9%) 454 (16.3%)
LPVritonavir 419 (5.0%) 316 (11.3%)
ATVritonavir 279 (3.3%) 454 (16.3%)
Other 943 (11.2%) 517 (18.6%)
Initiation year 2007 (2004 to 2009) 2007 (2003 to 2009) B0.001
VL measurements per person-year 1.95 (1.13 to 2.82) 3.38 (2.50 to 4.41) B0.001
At least one VL measurement B0.001
Yes 7522 (89.5%) 2683 (96.3%)
No 878 (10.5%) 103 (3.7%)
CCASAnet, Caribbean, Central and South America Network for HIV; IDU, injection drug use; MSM, men who have sex with men; NA-ACCORD,
North American AIDS Cohort Collaboration on Research and Design; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor;
VL, viral load. Antiretroviral agents: 3TC, lamivudine; FTC, emtricitabine; ABC, abacavir; ATV, atazanavir; D4T, stavudine; EFV, efavirenz; LPV,
lopinavir; NFV, nelfinavir; NVP, nevirapine; TDF, tenofovir; ZDV, zidovudine.
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Demographic and clinical characteristics of patients starting
ART in each cohort are shown in Table 1. Patients initiating
ART in CCASAnet were significantly younger (median 35 vs. 37
years old), more likely to be female (27% vs. 20%) and less
likely to have acquired HIV through injection drug use (2% vs.
12%) than Latinos initiating ART in NA-ACCORD (pB0.001
for all). Median follow-up was 3.3 years (interquartile range
(IQR): 1.2 to 6.0) for patients initiating ART in CCASAnet and
2.7 years (IQR: 1.0 to 5.6) for Latinos in NA-ACCORD.
Crude mortality rates were 2.1 and 1.4 per 100 person-
years for ART initiators in CCASAnet and NA-ACCORD,
respectively. All-cause mortality early after ART initiation
was higher in CCASAnet: 4.4% (95% CI: 4.0 to 4.9%) died
during the first year in CCASAnet compared with 1.5% (95%
CI: 1.0% to 2.0%) in NA-ACCORD (Figure 2). After one year,
the crude mortality rates were 1.28 and 1.33 per 100 person-
years for ART initiators who survived the first year in
CCASAnet and NA-ACCORD, respectively.
In multivariable Cox analyses, CCASAnet patients had a
higher hazard of mortality after ART initiation (adjusted hazard
ratio (AHR) 1.61; 95% CI: 1.32 to 1.96), adjusting for age, sex,
CD4 count, year of ART initiation, intravenous drug use, prior
AIDS diagnosis and ART regimen (Table 2). Among patients
who died in the first year, there was no significant difference
in CD4 count at ART initiation between CCASAnet and NA-
ACCORD (50 vs. 36 cells/mL, p0.35), though CCASAnet
patients were younger (37 vs. 42 years, p0.02) and less
likely to have an AIDS diagnosis before ART initiation (44% vs.
58%, p0.04; Supplementary Table 1).
The cumulative incidence of an ART treatment interrup-
tion, major treatment change, virologic failure and LFU were
lower for CCASAnet participants (Figure 3). The cumulative
incidence of an ART treatment interruption ]14 days was
lower in CCASAnet compared to NA-ACCORD at one year
(0.10 vs. 0.21) and five years (0.21 vs. 0.46). After controlling
for characteristics at ART initiation, the hazard ratio for
treatment interruption was significantly lower for patients in
CCASAnet (AHR: 0.46; 95% CI: 0.42 to 0.50; Table 2).
One and five years after ART initiation, the cumulative
incidence of a regimen change among patients initiating
ART in CCASAnet was 0.07 and 0.23, respectively, and
among Latinos initiating ART in NA-ACCORD, 0.13 and 0.39
(Figure 3b). Similarly, the hazard ratio for changing the initial
regimen was significantly lower for patients in CCASAnet
(AHR: 0.56; 95% CI: 0.51 to 0.62; Table 2). In CCASAnet, 70%
changed from an NNRTI to boosted PI, 24% from one PI to
another PI and 2% to a third-line drug. In NA-ACCORD, 41%
changed from an NNRTI to a boosted PI, 36% from one PI to
another PI and 21% changed to a regimen containing a third-
line drug.
Patients initiating ART in CCASAnet also had a lower
cumulative incidence of virologic failure (AHR 0.52, 95% CI:
0.48 to 0.57; Table 2 and Figure 3c). The results for virologic
failure were not appreciably different when patients were
censored at the start of a treatment interruption ]14 days;
the risk of virologic failure remained lower among CCASAnet
patients (AHR 0.51, 95% CI: 0.45 to 0.56; data not shown).
However, plasma VLwas measured less frequently for patients
in CCASAnet (median of 1.95 measurements per person per
year vs. 3.38 among Latinos in NA-ACCORD). Nonetheless, the
percentage of VL measurements after six months that were
detectable remained lower for patients in CCASAnet (9.6%;
6157/64,043) than for Latinos in NA-ACCORD (19.7%; 6400/
32,423; adjusted relative proportions of 0.53; 95%CI: 0.48
to 0.58).
Lastly, patients initiating ART in CCASAnet had a lower
cumulative incidence of LFU than patients initiating ART
in NA-ACCORD (Figure 3d). One and five years after ART
initiation, the cumulative incidence of LFU among patients
initiating ART in CCASAnet was 0.04 and 0.20, respectively,
and higher among Latinos initiating ART in NA-ACCORD, 0.12
and 0.36.
Subregion analyses
Brazilian CCASAnet sites and Brazilian patients enrolled in NA-
ACCORD were included in the primary analyses, but given the
large component of African migration to Brazil we performed
subregion analyses (Supplementary Table 2) that excluded
patients initiating ART in Brazil (n1792) and patients born
in Brazil initiating ART in North America (n2).The hazard ratio
of death in CCASAnet compared to NA-ACCORD was lower
when Brazilians were excluded (AHR: 1.27; 95% CI: 1.03 to
1.57), whereas there was little difference in the hazard ratios
of treatment interruption, regimen change or virologic failure.
Similarly, the percentage of VL measurements that were
detectable after six months remained lower for patients
initiating ART in CCASAnet in analyses excluding Brazil
(adjusted relative proportion0.52; 95% CI: 0.47 to 0.58).
Among the 804 patients initiating ART in Mexico and 156
Mexicans initiating ART in the United States or Canada, there
was insufficient evidence to suggest a difference in mortality
(AHR: 1.29; 95% CI: 0.43 to 3.85), although the hazard ratio
was in the same direction as primary analyses. Patients
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Figure 2. Cumulative mortality among Latino patients initiating
ART at Latin American (CCASAnet) and North American (NA-
ACCORD) sites. Time zero represents start of first antiretroviral
therapy regimen. Solid lines indicate 95% confidence intervals
around estimated incidence of mortality.
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initiating ART in Mexico had a lower hazard for virologic
failure (AHR: 0.45; 95% CI: 0.33 to 0.63), although again this
may have been driven by differences in the frequency of
measurements. The percentage of detectable VL measure-
ments was lower among patients initiating ART in Mexico
(adjusted relative proportion0.70; 95% CI: 0.43 to 1.15)
but this difference was not statistically significant.
Discussion
Latinos in the United States and Canada started ART with less
severe immunosuppression and had greater survival, parti-
cularly in the first 12 months of care, as compared with
individuals starting ART in Latin America, but Latinos in
North America also appear to be at greater risk for treatment
interruptions, treatment regimen changes, virologic failure
and LFU.
The lower risk of mortality observed among Latinos in North
America compared to those living in Latin America was most
pronounced in the early years of ART. Early mortality in
resource-limited settings has been well documented, and our
results are largely consistent with other comparisons between
resource-limited settings (primarily sub-Saharan Africa) and
Table 2. Comparison of all-cause mortality, treatment interruption, regimen change and virologic failure between Latinos initiating
antiretroviral therapy in NA-ACCORD and CCASAnet
Death hazard ratio
Treatment interruption
hazard ratio
Second-line regimen
switch hazard ratio
Virologic failure
hazard ratio
Cohort
NA-ACCORD Ref Ref Ref Ref
CCASAnet 1.61 (1.32 to 1.96) 0.46 (0.42 to 0.50) 0.56 (0.51 to 0.62) 0.52 (0.48 to 0.57)
Sex
Female Ref Ref Ref Ref
Male 1.02 (0.87 to 1.20) 0.75 (0.68 to 0.82) 0.76 (0.69 to 0.82) 0.75 (0.68 to 0.82)
Age
20 0.73 (0.52 to 1.04) 1.47 (1.26 to 1.73) 1.25 (1.06 to 1.47) 1.53(1.30 to 1.80)
30 0.82 (0.71 to 0.95) 1.22 (1.12 to 1.34) 1.09 (1.00 to 1.20) 1.04 (0.95 to 1.14)
40 Ref Ref Ref Ref
50 1.31 (1.20 to 1.43) 0.82 (0.76 to 0.88) 0.98 (0.92 to 1.04) 0.93 (0.87 to 0.99)
60 1.77 (1.42 to 2.20) 0.68 (0.55 to 0.83) 0.99 (0.83 to 1.17) 0.78 (0.65 to 0.94)
Clinical AIDS at baseline
No Ref Ref Ref Ref
Yes 1.27 (1.07 to 1.49) 1.05 (0.94 to 1.17) 1.04 (0.94 to 1.15) 0.94 (0.85 to 1.05)
Baseline CD4 count, cells/mL
50 2.28 (1.80 to 2.88) 0.88 (0.78 to 0.99) 1.32 (1.17 to 1.49) 1.05 (0.93 to 1.18)
100 1.68 (1.34 to 2.10) 0.85 (0.76 to 0.95) 1.22 (1.08 to 1.36) 1.00 (0.90 to 1.13)
200 1.09 (0.93 to 1.28) 0.90 (0.84 to 0.95) 1.05 (0.98 to 1.13) 0.90 (0.85 to 0.97)
350 Ref Ref Ref
Initiation year
2000 0.82 (0.62 to 1.09) 1.33 (1.16 to 1.54) 0.86 (0.74 to 1.01) 1.88 (1.62 to 2.18)
2002 0.92 (0.79 to 1.07) 1.25 (1.15 to 1.35) 0.86 (0.79 to 0.94) 1.56 (1.44 to 1.70)
2004 1.00 (0.90 to 1.11) 1.15 (1.08 to 1.22) 0.89 (0.84 to 0.94) 1.27 (1.20 to 1.36)
2006 Ref Ref Ref Ref
2008 0.97 (0.85 to 1.10) 0.85 (0.79 to 0.91) 1.29 (1.20 to 1.38) 0.85 (0.79 to 0.92)
2010 1.02 (0.82 to 1.27) 0.74 (0.65 to 0.84) 1.93 (1.71 to 2.17) 0.95 (0.83 to 1.10)
ART regimen class
NNRTI Ref Ref Ref Ref
PI 0.93 (0.77 to 1.13) 1.18 (1.06 to 1.31) 1.05 (0.95 to 1.17) 1.38 (1.24 to 1.53)
Other 1.27 (1.00 to 1.60) 1.50 (1.34 to 1.69) 1.73 (1.53 to 1.94) 1.70 (1.50 to 1.91)
History of IDU
No Ref Ref Ref Ref
Yes 1.64 (1.21 to 2.21) 1.42 (1.22 to 1.65) 1.28 (1.08 to 1.51) 1.71 (1.46 to 2.01)
Estimates presented as hazard ratio (95% confidence interval). CCASAnet, Caribbean, Central and South America Network for HIV; IDU, injection
drug use; NA-ACCORD, North American AIDS Cohort Collaboration on Research and Design; NNRTI, non-nucleoside reverse transcriptase
inhibitor; Ref, reference category; PI, protease inhibitor. Continuous variables were modelled using restricted cubic splines, and the hazard ratios
and confidence intervals shown for age, baseline CD4 count, and year of ART initiation represent predicted values estimated from the model.
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North America and Europe [21]. Patients initiating ART in Latin
America had a greater degree of immunosuppression.
Although cause of death was not available, other studies
have reported AIDS-related conditions as the leading cause of
early mortality after treatment initiation in Latin America, and
this predominance has not changed despite the improved
survival observed in the era of modern combination ART
regimens [2225].
Compared to non-Hispanic whites, Latinos in the United
States as a group are diagnosed at a more advanced HIV
disease, and foreign-born, non-English speaking and male
Latinos are at particularly high risk of delayed diagnosis
[2632]. Barriers to engagement in HIV care in the United
States may be greater for Latinos than other ethnic groups.
An analysis of 2010 data found that among Hispanics or
Latinos diagnosed with HIV, rates at all stages of the care
continuum were lower than among non-Hispanic whites [3].
A recent study of a predominantly Hispanic HIV cohort in
Texas, found that 46% of patients lacked insurance and an
additional 14% were receiving Medicaid [5]. There can also
be particular challenges for Latinos due to linguistic bar-
riers and differences in patient-provider communication.
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Figure 3. Cumulative incidence of antiretroviral therapy (ART) treatment interruption, ART regimen change, virologic failure and loss to
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and NA-ACCORD patients using a competing risks model where time zero represents the start of the first ART regimen. Solid lines indicate
95% confidence intervals around estimated incidence of treatment interruption. (a) Cumulative incidence of a 14-day or greater ART
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For example, prior studies have identified less patient-
centred and psychosocial language use by HIV clinicians
treating Hispanics versus non-Hispanics [68].
Prior studies have also identified important differences
among native and foreign-born Latinos in the United States,
which may be representative of broader geographic trends.
Studies from the United States found that foreign-born
Latino males are more likely to have acquired HIV through
heterosexual contact as compared to US-born Latinos.
Among HIV-positive Latinas, foreign-born women were older
at first sexual contact, had fewer episodes of non-HIV
sexually transmitted diseases and lower rates of drug and
alcohol abuse [27,33,34].
We examined health outcomes at CCASAnet sites in
aggregate, but prior studies have found that mortality and
programme retention vary considerably between countries in
Latin America, which likely reflects differences in the under-
lying demographics of the HIV epidemic in the region, as well
as local social and economic characteristics [9,1113,35,36].
Heterogeneity in mortality could be related to different
programme retention and death ascertainment. Rates of
treatment change also vary by CCASAnet sites, with geo-
graphic differences in specific toxicities as well as uneven
availability of second- and third-line medications, which may
be a source of possible confounding [37,38]. The cumulative
incidence of regimen change in NA-ACCORD was higher than
in CCASAnet, and 21% of patients changing regimens switched
to a third-line agent in NA-ACCORD, compared to 2% in
CCASAnet.This figuremay reflect a greater availability of third-
line agents driving a higher cumulative incidence of regimen
change, particularly if the change occurs for tolerability issues
(which might not be an option in CCASAnet countries with a
more limited ART selection). However, it should be noted that
cumulative incidence of virologic failure was also higher in NA-
ACCORD, so the greater utilization of third-line agents may
simply reflect a greater burden of HIV drug resistance.
A strength of this study was the large number of subjects
contributing data from multiple countries. However, the
largest number of North American Latino patients with
known foreign birth location had migrated from Mexico,
whereas the majority of CCASAnet patients were located in
South America. Limitations of our data included the pro-
portion of patients with no reported country of birth in NA-
ACCORD. Other limitations included the lack of information
on causes of death and potential confounding of the
treatment interruption analysis related to how accurately
sites record gaps in ART use (i.e. adherence) versus gaps in
prescriptions for ART. Although we assessed time to virologic
failure, we did not assess the role of adherence and viral
resistance in treatment failure, nor toxicity or other reasons
for ART change.
Conclusions
Mortality rates were higher in Latin America, possibly due to
treatment initiation at more advanced stages of HIV disease,
whereas treatment interruption, major regimen modification,
virologic failure and LFU were higher in North America,
where barriers to receiving quality HIV care may be higher for
Latino populations. These results emphasize once again the
need for early diagnosis and treatment initiation in Latin
America and reinforce the key role of ensuring US Latino HIV
patients have consistent access to care to improve treatment
outcomes.
Authors’ affiliations
1Investigaciones Clı´nicas, Fundacio´n Hue´sped, Buenos Aires, Argentina; 2Division
of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN,
USA; 3Department of Biostatistics, Vanderbilt University School of Medicine,
Nashville, TN, USA; 4Department of Epidemiology, Johns Hopkins Bloomberg
School of Public Health, Baltimore, MD, USA; 5Department of Medicine, University
of North Carolina, Chapel Hill, NC, USA; 6Department of Internal Medicine,
Universidad Central del Caribe, Bayamo´n, Puerto Rico; 7Instituto de Pesquisa
Clinica Evandro Chagas, Fundac¸a˜o Oswaldo Cruz, Rio de Janeiro, Brazil; 8Fundacio´n
Arriara´n and Facultad de Medicina, Universidad de Chile, Santiago, Chile; 9Instituto
Honduren˜o de Seguridad Social and Hospital Escuela Universitario, Tegucigalpa,
Honduras; 10Instituto Nacional de Ciencias Me´dicas y Nutricio´n, Mexico City,
Mexico; 11Instituto de Medicina Tropical Alexander von Humboldt, Lima, Peru;
12Division of Infectious Diseases, University of Alabama at Birmingham, Birming-
ham, AL, USA; 13Division of General Internal Medicine, Massachusetts General
Hospital, and Harvard Medical School, Boston, MA, USA; 14Division of Infectious
Diseases, University of Washington, Seattle, WA, USA; 15Infectious Diseases
Section, Michael E. De Bakey VAMC, Baylor College of Medicine, Houston, TX,
USA; 16Department of Medicine, Johns Hopkins University, Baltimore, MD, USA
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CC, BG, RDM, CMG, BES and PC conceived and designed the study; CC, MJG,
CMG, BES and PC contributed to data collection and management. CMG and
BES analyzed the data. All authors interpreted the data. CC, JRK, MJG, CMG,
BES and PC drafted the manuscript. All authors critically revised the article and
approved the final version of the manuscript.
Acknowledgements
We gratefully acknowledge all patients, caregivers and data managers involved
in the CCASAnet and NA-ACCORD cohorts.
Funding
NA-ACCORD: This work was supported by the National Institutes of Health, USA
(grants U01-AI069918, U01-AA013566, U24-AA020794, U01-AA020790, U01-
AI31834, U01-AI34989, U01-AI34993, U01-AI34994, U01-AI35004, U01-AI35039,
U01-AI35040, U01-AI35041, U01-AI35042, U01-AI37613, U01-AI37984, U01-
AI38855, U01-AI38858, U01-AI42590, U01-AI68634, U01-AI68636, U01-AI69432,
U01-AI69434, U01-DA036935, U01-HD32632, U10-EY08052, U10-EY08057,
U10-EY08067, U54-MD007587, UL1-RR024131, UL1-TR000083, UM1-AI35043,
G12-MD007583, K01-AI071754, K01-AI093197, K23-EY013707, K24-DA00432,
K24-AI065298, KL2-TR000421, MO1-RR-00052, N02-CP55504, P30-AI027763,
P30-AI094189, P30-AI27757, P30-AI27767, P30-AI036219, P30-AI50410,
P30-AI54999, P30-MH62246, P30 AI110527, R01-AA16893, R01-CA165937,
R01-DA04334, R01-DA11602, R01-DA12568, R24-AI067039, R56-AI102622,
F31-DA037788, Z01-CP010214, and Z01-CP010176); Disease Control and
Prevention, USA (contract CDC200-2006-18797); the Agency for Healthcare
Research and Quality, USA (contract 90047713); the Health Resources and
Services Administration, USA (contract 90051652); National Institute of Mental
Health of the National Institutes of Health (grant K23MH100978); the Canadian
Institutes of Health Research, Canada (grants TGF-96118, HCP-97105, CBR-
86906, CBR-94036); Canadian Institutes of Health Research New Investigator
Award (A. Burchell); Ontario Ministry of Health and Long Term Care; and the
Government of Alberta, Canada. Additional support was provided by the
Intramural Research Programof the National Cancer Institute, National Institutes
of Health.
CCASAnet: This work was supported by the National Institutes of Health, USA
(grant 2-U01-AI069923).
Disclaimer
The content is solely the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of Health.
Author information
NA-ACCORD collaborating cohorts and representatives
Cesar C et al. Journal of the International AIDS Society 2016, 19:20684
http://www.jiasociety.org/index.php/jias/article/view/20684 | http://dx.doi.org/10.7448/IAS.19.1.20684
8
AIDS Link to the IntraVenous Experience: Gregory D Kirk
Adult AIDS Clinical Trials Group Longitudinal Linked Randomized Trials:
Constance A Benson and Ronald J Bosch
Fenway Health HIV Cohort: Stephen Boswell, Chris Grasso and Kenneth
H Mayer
HAART Observational Medical Evaluation and Research: Robert S Hogg,
P Richard Harrigan, Julio SG Montaner, Angela Cescon and Hasina Samji
HIV Outpatient Study: John T Brooks and Kate Buchacz
HIV Research Network: Kelly A Gebo and Richard D Moore
Johns Hopkins HIV Clinical Cohort: Richard D Moore
John T. Carey Special Immunology Unit Patient Care and Research Database,
Case Western Reserve University: Benigno Rodriguez
Kaiser Permanente Mid-Atlantic States: Michael A Horberg
Kaiser Permanente Northern California: Michael J Silverberg
Longitudinal Study of Ocular Complications of AIDS: Jennifer E Thorne
Multicenter Hemophilia Cohort StudyII: James J Goedert
Multicenter AIDS Cohort Study: Lisa P Jacobson and Gypsyamber D’Souza
Montreal Chest Institute Immunodeficiency Service Cohort: Marina B Klein
Ontario HIV Treatment Network Cohort Study: Sean B Rourke, Ann N Burchell
and Anita R Rachlis
Retrovirus Research Center, Bayamon Puerto Rico: Robert F Hunter-Mellado
and Angel M Mayor
Southern Alberta Clinic Cohort: M John Gill
Studies of the Consequences of the Protease Inhibitor Era: Steven G Deeks and
Jeffrey N Martin
The Study to Understand the Natural History of HIV/AIDS in the Era of Effective
Therapy: Pragna Patel and John T Brooks
University of Alabama at Birmingham 1917 Clinic Cohort: Michael S Saag,
Michael J Mugavero and James Willig
University of North Carolina at Chapel Hill HIV Clinic Cohort: Joseph J Eron and
Sonia Napravnik
University of Washington HIV Cohort: Mari M Kitahata, Heidi M Crane and
Daniel R Drozd
Veterans Aging Cohort Study: Amy C Justice, Robert Dubrow and David Fiellin
Vanderbilt Comprehensive Care Clinic HIV Cohort: Timothy R Sterling, David
Haas, Peter Rebeiro, Sally Bebawy and Megan Turner
Women’s Interagency HIV Study: Stephen J Gange and Kathryn Anastos
NA-ACCORD study administration
Executive Committee: Richard D Moore, Michael S Saag, Stephen J Gange, Mari
M Kitahata, Keri N Althoff, Rosemary G McKaig, Amy C Justice and Aimee
M Freeman
Administrative Core: Richard D Moore, Aimee M Freeman and Carol Lent
Data Management Core: Mari M Kitahata, Stephen E Van Rompaey, Heidi
M Crane, Daniel R Drozd, Liz Morton, Justin McReynolds and William B Lober
Epidemiology and Biostatistics Core: Stephen J Gange, Keri N Althoff, Alison
G Abraham, Bryan Lau, Jinbing Zhang, Yuezhou Jing, Elizabeth Golub, Shari
Modur, Cherise Wong, Bin Liu, Weiqun Tong and Brenna Hogan
CCASAnet cohorts and representatives
Fundacio´n Hue´sped, Buenos Aires, Argentina, principal investigator (PI): Pedro
Cahn, MD, PhD
Instituto de Pesquisa Clinica Evandro Chagas, Fundac¸a˜o Oswaldo Cruz, Rio de
Janeiro, Brazil, PI: Beatriz Grinsztejn, MD, PhD
Universidad de Chile, Santiago, Chile, PI: Marcelo Wolff Reyes, MD
Le Groupe Haı¨tien d’Etude du Sarcome de Kaposi et des Infections
Opportunistes, Port-au-Prince, Haiti, PI: Jean W Pape, MD
Instituto Honduren˜o de Seguridad Social and Hospital Escuela, Tegucigalpa,
Honduras, PI: Denis Padgett, MD
Instituto Nacional de Ciencias Me´dicas y Nutricio´n, Mexico City, Mexico, PI:
Juan Sierra Madero, MD
Instituto de Medicina Tropical Alexander von Humboldt, Lima, Peru, PI:
Eduardo Gotuzzo, MD
Vanderbilt University, Nashville, TN, USA, PI: Catherine McGowan, MD
CCASAnet PIs
Pedro Cahn (pedro.cahn@huesped.org.ar)
Catherine McGowan (c.mcgowan@Vanderbilt.Edu)
References
1. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2013.
Geneva: UNAIDS; 2013.
2. Ennis SR, Rios-Vargas M, Albert NG. The Hispanic population: 2010. U.S.
Department of Commerce, U.S. Census Bureau; 2011.
3. Gant Z, Bradley H, Hu X, Skarbinski J, Hall HI, Lansky A, et al. Hispanics or
Latinos living with diagnosed HIV: progress along the continuum of HIV care 
United States, 2010. MMWR Morb Mortal Wkly Rep. 2014;63(40):88690.
4. Centers for Disease Control and Prevention. HIV surveillance report, 2011.
Atlanta, GA: US Department of Health and Human Services; 2013.
5. Taylor BS, Liang Y, Garduno LS, Walter EA, Gerardi MB, Anstead GM, et al.
High risk of obesity and weight gain for HIV-infected uninsured minorities.
J Acquir Immune Defic Syndr. 2014;65(2):e3340.
6. Garland JM, Andrade AS, Page KR. Unique aspects of the care of HIV-
positive Latino patients living in the United States. Curr HIV/AIDS Rep. 2010;
7(3):10716.
7. Beach MC, Saha S, Korthuis PT, Sharp V, Cohn J,Wilson I, et al. Differences in
patient-provider communication for Hispanic compared to non-Hispanic white
patients in HIV care. J Gen Intern Med. 2010;25(7):6827.
8. Chen NE, Gallant JE, Page KR. A systematic review of HIV/AIDS survival and
delayed diagnosis among Hispanics in the United States. J Immigr Minor
Health. 2012;14(1):6581.
9. Tuboi SH, Schechter M, McGowan CC, Cesar C, Krolewiecki A, Cahn P, et al.
Mortality during the first year of potent antiretroviral therapy in HIV-1-infected
patients in 7 sites throughout Latin America and the Caribbean. J Acquir
Immune Defic Syndr. 2009;51(5):61523.
10. Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A, Nash D, et al. Early
loss of HIV-infected patients on potent antiretroviral therapy programmes in
lower-income countries. Bull World Health Organ. 2008;86(7):55967.
11. Wolff MJ, Cortes CP, Shepherd BE, Beltran CJ, Chilean ACSG. Long-term
outcomes of a national expanded access program to antiretroviral therapy: the
Chilean AIDS cohort. J Acquir Immune Defic Syndr. 2010;55(3):36874.
12. Gupta A, Nadkarni G, Yang WT, Chandrasekhar A, Gupte N, Bisson GP, et al.
Early mortality in adults initiating antiretroviral therapy (ART) in low  and
middle-income countries (LMIC): a systematic review and meta-analysis. PLoS
One. 2011;6(12):e28691.
13. Carriquiry G, Fink V, Koethe J, Giganti M, Jayathilake K, Cahn P, et al.
Mortality and loss to follow-up among HIV-infected persons on long-term
antiretroviral therapy in Latin America and the Caribbean. J Int AIDS Soc.
2015;18(1):20016.
14. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al.
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy:
comparison between low-income and high-income countries. Lancet.
2006;367(9513):81724.
15. Sanne IM, Westreich D, Macphail AP, Rubel D, Majuba P, Van Rie A. Long
term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban
South Africa: a prospective cohort study. J Int AIDS Soc. 2009;12:38.
16. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, et al.
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected
patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;
373(9672):135263.
17. McGowan CC, Cahn P, Gotuzzo E, Padgett D, Pape JW, Wolff M, et al.
Cohort Profile: Caribbean, Central and South America Network for HIV research
(CCASAnet) collaboration with in the International Epidemiologic Databases to
Evaluate AIDS (IeDEA) programme. Int J Epidemiol. 2007;36(5):96976.
18. Gange SJ, Kitahata MM, Saag MS, Bangsberg DR, Bosch RJ, Brooks JT, et al.
Cohort profile: the North American AIDS Cohort Collaboration on Research and
Design (NA-ACCORD). Int J Epidemiol. 2007;36(2):294301.
19. Harrell FE. Regression modeling strategies with applications to linear
models, logistic regression, and survival analysis. New York: Springer-Verlag;
2001.
20. Rubin DB, Schenker N. Multiple imputation in health-care databases: an
overview and some applications. Stat Med. 1991;10(4):58598.
21. Boulle A, Schomaker M, May MT, Hogg RS, Shepherd BE, Monge S, et al.
Mortality in patients with HIV-1 infection starting antiretroviral therapy in
South Africa, Europe, or North America: a collaborative analysis of prospective
studies. PLoS Med. 2014;11(9):e1001718.
22. Perez E, Toibaro JJ, Losso MH. [HIV patient hospitalization during the pre
and post-HAART era]. Medicina (B Aires). 2005;65(6):4828.
23. Pacheco AG, Tuboi SH, May SB, Moreira LF, Ramadas L, Nunes EP, et al.
Temporal changes in causes of death among HIV-infected patients in the
HAART era in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr. 2009;
51(5):62430.
24. Grinsztejn B, Luz PM, Pacheco AG, Santos DV, Velasque L, Moreira RI, et al.
Changing mortality profile among HIV-infected patients in Rio de Janeiro,
Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era.
PLoS One. 2013;8(4):e59768.
Cesar C et al. Journal of the International AIDS Society 2016, 19:20684
http://www.jiasociety.org/index.php/jias/article/view/20684 | http://dx.doi.org/10.7448/IAS.19.1.20684
9
25. Grinsztejn B, Veloso VG, Friedman RK, Moreira RI, Luz PM, Campos DP,
et al. Early mortality and cause of deaths in patients using HAART in Brazil and
the United States. AIDS. 2009;23(16):210714.
26. Espinoza L, Hall HI, Hu X. Increases in HIV diagnoses at the U.S.-Mexico
border, 20032006. AIDS Educ Prev. 2009;21(Suppl 5):1933.
27. Espinoza L, Hall HI, Selik RM, Hu X. Characteristics of HIV infection among
Hispanics, United States 20032006. J Acquir Immune Defic Syndr. 2008;
49(1):94101.
28. Hall HI, Byers RH, Ling Q, Espinoza L. Racial/ethnic and age disparities in
HIV prevalence and disease progression among men who have sex with men in
the United States. Am J Public Health. 2007;97(6):10606.
29. Hall HI, Geduld J, Boulos D, Rhodes P, An Q, Mastro TD, et al. Epidemiology
of HIV in the United States and Canada: current status and ongoing challenges.
J Acquir Immune Defic Syndr. 2009;51(Suppl 1):S1320.
30. Hall HI, McDavid K, Ling Q, Sloggett A. Determinants of progression to
AIDS or death after HIV diagnosis, United States, 1996 to 2001. Ann Epidemiol.
2006;16(11):82433.
31. Wohl AR, Tejero J, Frye DM. Factors associated with late HIV testing for
Latinos diagnosed with AIDS in Los Angeles. AIDS Care. 2009;21(9):120310.
32. Torrone EA, Thomas JC, Leone PA, Hightow-Weidman LB. Late diagnosis of
HIV in young men in North Carolina. Sex Transm Dis. 2007;34(11):8468.
33. Prosser AT, Tang T, Hall HI. HIV in persons born outside the United States,
20072010. JAMA. 2012;308(6):6017.
34. Castillo-Mancilla J, Allshouse A, Collins C, Hastings-Tolsma M, Campbell TB,
Mawhinney S. Differences in sexual risk behavior and HIV/AIDS risk factors
among foreign-born and US-born Hispanic women. J Immigr Minor Health.
2012;14(1):8999.
35. Yiannoutsos CT, Johnson LF, Boulle A, Musick BS, Gsponer T, Balestre E,
et al. Estimated mortality of adult HIV-infected patients starting treatment
with combination antiretroviral therapy. Sex Transm Infect. 2010;88(Suppl 2):
i3343.
36. World Bank. World bank open data 2014 [cited 2015 Aug 6]. Available
from: http://data.worldbank.org/
37. Cesar C, Shepherd BE, Krolewiecki AJ, Fink VI, Schechter M, Tuboi SH, et al.
Rates and reasons for early change of first HAART in HIV-1-infected patients in
7 sites throughout the Caribbean and Latin America. PLoS One. 2010;5(6):
e10490.
38. Cesar C, Shepherd BE, Jenkins CA, Ghidinelli M, Castro JL, Veloso VG, et al.
Use of third line antiretroviral therapy in Latin America. PLoS One. 2014;
9(9):e106887.
Cesar C et al. Journal of the International AIDS Society 2016, 19:20684
http://www.jiasociety.org/index.php/jias/article/view/20684 | http://dx.doi.org/10.7448/IAS.19.1.20684
10
